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Abstract
Endochondral ossification is the process by which the appendicular skeleton, facial bones, vertebrae and medial clavicles are
formed and relies on the tight control of chondrocyte maturation. Fibroblast growth factor receptor (FGFR)3 plays a role in
bone development and maintenance and belongs to a family of proteins which differ in their ligand affinities and tissue
distribution. Activating mutations of the FGFR3 gene lead to craniosynostosis and multiple types of skeletal dysplasia with
varying degrees of severity: thanatophoric dysplasia (TD), achondroplasia and hypochondroplasia. Despite progress in the
characterization of FGFR3-mediated regulation of cartilage development, many aspects remain unclear. The aim and the
novelty of our study was to examine whole gene expression differences occurring in primary human chondrocytes isolated
from normal cartilage or pathological cartilage from TD-affected fetuses, using Affymetrix technology. The phenotype of the
primary cells was confirmed by the high expression of chondrocytic markers. Altered expression of genes associated with
many cellular processes was observed, including cell growth and proliferation, cell cycle, cell adhesion, cell motility,
metabolic pathways, signal transduction, cell cycle process and cell signaling. Most of the cell cycle process genes were
down-regulated and consisted of genes involved in cell cycle progression, DNA biosynthesis, spindle dynamics and
cytokinesis. About eight percent of all modulated genes were found to impact extracellular matrix (ECM) structure and
turnover, especially glycosaminoglycan (GAG) and proteoglycan biosynthesis and sulfation. Altogether, the gene expression
analyses provide new insight into the consequences of FGFR3 mutations in cell cycle regulation, onset of pre-hypertrophic
differentiation and concomitant metabolism changes. Moreover, impaired motility and ECM properties may also provide
clues about growth plate disorganization. These results also suggest that many signaling pathways may be directly or
indirectly altered by FGFR3 and confirm the crucial role of FGFR3 in the control of growth plate development.
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Introduction
Endochondral ossification, the process by which the appendicular
skeleton, facial bones, vertebrae and medial clavicles are formed,
relies on a tightly controlled chondrocyte maturation process,
characterized by successive changes in cell morphology and gene
expression. Maturation of chondrocytes leads to the formation of the
growth plate, which consists of three main zones containing resting,
proliferative or hypertrophic chondrocytes. In order for endochon-
dral ossification to occur, precise temporal and spatial coordination
between the different factors providing both positive and negative
signals at each step of the process is essential. These factors can act in
a synergistic manner, or form negative feedback loops and may
participate in signaling pathways such as parathyroid hormone
related peptide (PTHrP), Indian hedgehog (IHH), C-type natriuretic
peptide (CNP), bone morphogenetic protein (BMP), Wnt and
fibroblast growth factor receptor (FGFR) pathways [1–3]. Nitric
oxide, hypoxia and their downstream effectors have also been shown
to act as major key regulators of endochondral ossification [4–8]. In
addition, cell adhesion pathways, cytoskeleton structure and
dynamics and intraflagellar transport have emerged as crucial
regulators of both proliferation and hypertrophy [9–15]. Intracellular
pathways triggered by these signals, as well as their targets are still
poorly defined and only a few downstream transcription factors have
been studied including the SOX, RUNX, AP1 and the CREB/ATF
families [16,17] as well as Nkx3.2 [18], Snail1 [19] and BAG-1 [20].
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7633The importance of FGFR3 in early bone development was
established from the association of point mutations in FGFR3 with
dominant chondrodysplasias ranging in severity from mild
(hypochondroplasia [HCH] and achondroplasia [ACH]) to severe
(thanatophoric dysplasia [TD]), [21,22]. Two TD subtypes have
been defined based on the clinical presentation: type I (TDI),
characterized by marked shortness and bowing of the long bones
and type II (TDII), characterized by straight femurs and a
moderate to severe cloverleaf skull deformity. Histopathology of
the growth plate reveals a disruption of endochondral ossification.
It is generally accepted that FGFR3 is a negative regulator of
bone growth and that constitutive activation of FGFR3 signaling is
the cause of these disorders [23,24]. Several signaling pathways
have been shown to be affected by FGFR3 activation including
STAT1/3 [25–27], STAT5 [28], MEK1 [29] and ERK1/2
[30,31]. Different in vitro stimulation studies performed on rat
chondrosarcoma (RCS) and primary chondrocytes using FGFs
revealed decreased cell proliferation due to cell cycle arrest at G1,
up-regulation of c-jun, junD, cyclin-D1, NF-KB, STAT1/3 and
p21, activation of members of the pRb family, inactivation of Id1,
cyclin-E-Cdk2 complex and reduced AKT phosphorylation
[26,32–35]. A two step mechanism leading to cell cycle arrest
has also been proposed based on a time course microarray analysis
of FGF stimulated RCS cells [36]. The first "growth arrest
initiation" step includes down-regulation of key cell cycle genes
and some positive regulators of proliferation, and the second
"growth arrest maintenance" step is characterized by Cdk
inhibition, up-regulation of p21, Rb and p130 dephosphorylation
and down-regulation of additional cell cycle protein genes [36].
Taken together, these data support a model in which excessive
FGFR3 signaling in chondrocytes reduces bone growth by
inhibiting chondrocyte proliferation and some aspects of differen-
tiation. Despite progress in characterization of the FGFR3-
mediated regulation of cartilage, many aspects of this regulation
remain unclear and downstream events are poorly understood.
The aim of the present study was to examine whole gene
expression changes in human pathological cartilage of FGFR3-
related chondrodysplasias. Control and TDI primary human
chondrocyte mRNA expression levels were compared using
Affymetrix technology. The analysis of genes associated with cell
functions provides new insight into consequences of FGFR3
mutations on cell cycle regulation, onset of pre-hypertrophic
differentiation, concomitant metabolism changes and adhesion.
These results also suggest that many signaling pathways may be
affected by FGFR3 and confirm the crucial role of FGFR3 in
skeletal disease.
Results
Sample collection
The study was performed using two batches of human
chondrocyte primary cultures derived from seven TDI and four
control fetuses without skeletal pathology, aged 18 to 25 weeks.
The radiological features of TDI such as narrow trunk, curved
femurs and platyspondyly were observed in all pathological fetuses.
The chondrocytic phenotype of the primary cells was assessed
before performing the microarray experiment. Cultured cells
retained chondrocytic morphology and a high expression of
cartilage specific genes such as aggrecan, collagen type II compared to
collagen type I and SOX9 was observed by RT-PCR (data not
shown). Four heterozygous Arg248Cys and three Tyr373Cys
mutations were identified in the FGFR3 extracellular domain by
genomic DNA sequencing of TD primary chondrocytes. The
control primary chondrocytes did not contain mutations in the
FGFR3 domains (Supplementary data S1).
In silico analysis
The transcriptome of the normal chondrocyte. After data
normalization, intensity signals above background (median log2
signal intensity above 4) could be detected for 22000 probe sets in
human control chondrocytes (supplementary data S2). These
probe sets were found to match 11777 known genes, of which
7505 were eligible for functional annotation using Ingenuity
Pathway Analysis (IPA). Identified biological functions included
cell cycle (859 genes, p-value=9 10
241), gene expression (1231
genes, p-value=6 10
234), cellular growth and proliferation (1188
genes, p-value=8 10
234) and cell death (1658 genes, p-value=8
10
232). Details are given in Figure 1 and supplementary data S3.
Expression values of cartilage specific markers were compiled in
an attempt to characterize the phenotype of the primary
chondrocytes. Most of the genes characteristic of the proliferative
zone were highly expressed, including FGFR3, GADD45A and
Figure 1. IPA analysis of biological processes associated with expressed genes in the normal chondrocyte. The classical IPA bar chart
displays biological functions along the x-axis. The y-axis displays the - (log) significance. Functions are listed from most significant (higher bars) to
least significant (lower bars) and the orange horizontal line denotes the threshold for significance (p-value of 0.05).
doi:10.1371/journal.pone.0007633.g001
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as NKX3.2, SOX9 and BMP2 were also observed. Major
components of the extra-cellular matrix such as collagen type II,
IX or XI, aggrecan and glypican were likewise highly expressed. Pre-
hypertrophic markers, like Gli or RUNX2 were expressed. In
contrast, no expression of hypertrophic markers such as collagen type
X, alkaline phosphatase, IHH, PTHrP,o rPTH was observed
(Figure 2).
Biological process modulated by FGFR3 constitutive
activation. A two way ANOVA was performed to identify
516 probe sets differentially expressed between TDI and normal
chondrocytes, with at least a 50% change in expression level.
These probe sets matched to 427 known genes in IPA, of which
291 were eligible for functional annotation. Up regulated genes
(265) were as frequent as down-regulated ones (251), with 27 genes
showing a fold change greater than 5-fold (supplementary data
S4).
Functional annotation using IPA and FatiGO+ showed that
modulated genes were involved in multiple biological processes.
All functions usually considered to be affected by FGFR3
mutations were represented: cell cycle (65 genes), cellular growth
and proliferation (111 genes), cell death (75 genes) and cell
signaling (35 genes). This analysis also revealed differences in the
expression of genes involved in metabolism (lipid, nucleic acid and
carbohydrate: 63 genes), in cell-cell interaction (67 genes), cell
adhesion (33 genes) and cell motility (51 genes) processes (Figure 3
and supplementary data S4).
Most of the ‘‘cell cycle process’’ genes which were were down-
regulated were also involved in cell cycle progression and
checkpoints (e.g. BUB1, CDC2, CDKN2C, CCNA1, CCNB2,
E2F8), DNA biosynthesis and replication (e.g. NFIA, PPP2A,
RRM2), spindle and kinetochore assembly (e.g. BIRC5, CENPH,
KIF23, NDC80, TUBB2B) chromosome segregation and cytokine-
sis (e.g. CDC20, KIF2C, KIF14, KIF15, KIF23, SEPT6). Conversely,
genes promoting G1 progression, especially cyclin D1 and UHMK1
were up-regulated whereas p18, an inhibitor of G1 progression was
down-regulated. Details are given in Figure 4.
In addition, about eight percent of the modulated genes are
related to extracellular matrix (ECM) structure and dynamics
(Figure 5). Expression of several genes coding basement membrane
or ECM structural components, as well as proteins involved in
aggrecan turnover such as ADAMTS1 and ADAMTS5, was altered
in TDI chondrocytes. Many genes coding enzymes involved in the
glycosaminoglycan or proteoglycan biosynthesis and sulfation
pathways were also modulated e.g. hyaluronan synthase 3 (HAS3),
xylosyl-transferase (XYLT1), glactosyltransferases (GALNT3,
B3GALNT2, B4GALT5, GALNTL2) glucuronyltransferases
(B3GAT2) and glycosyltransferases (B3GALTL, GLT25D2) as well
as PAPSS2, coding for one of the two synthetases producing PAPS,
SLC26A2 and several other genes encoding sulfotransferases,
including CHST3, HS3ST3A1, HS3ST3B1 and HS6ST2.
Likewise, modulated genes include genes involved in cell-cell
interaction or adhesion (CD44, NCAM1, integrins, cadherins and
protocadherins) and cell motility processes (regulation of actin
cytoskeleton, myosin), such as genes that regulate or act along
the Rac1 and CDC42 RhoGTPase signaling pathways. In
particular, MTSS1, NME1 and RND3 were up-regulated whereas
IQGAP3 and TIAM2 were down-regulated (Figure 5).
Canonical pathways and in silico promoter
analysis. The percentage of genes differently modulated
between TDI and control chondrocytes in a given pathway was
low and only two metabolic (chondroitin and keratan sulfate
biosynthesis) and four signaling pathways (p53, FGF, G-protein
coupled receptor signaling and thyroid hormone nuclear signaling
Figure 2. Expression level of cartilage maturation stage
specific marker genes in the normal chondrocyte. Genes were
classified according to their role in particular stages of cartilage
maturation. Their Log2 intensity expression values are shown on the
right, with high expression values (red), mid values (orange) and low
values (blue). Expression values below 4 are considered as background
(white). Most expressed genes belong to the proliferative group,
suggesting that primary chondrocytes were mainly in a proliferative
state.
doi:10.1371/journal.pone.0007633.g002
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than 5%. Despite the absence of statistically significant
enrichment, many other signaling pathways may be affected as
several modulated genes belong to the TGFb/BMP, Wnt,
Hedgehog, PI3K/AKT, JNK, p38 MAPK and 14-3-3 signaling
pathways (Figure 6 and supplementary data S4). Moreover, some
Figure 3. IPA analysis of biological processes associated with modulated genes in TDI chondrocytes. Biological functions associated
with significantly modulated genes are shown along the x axis of the bar graph and the - (log) significance along the y-axis. Functions are listed from
most significant (higher bars) to least significant (lower bars). The threshold for significance (p-value of 0.05) is shown as an orange horizontal line.
doi:10.1371/journal.pone.0007633.g003
Figure 4. Normal v. TDI chondrocytes: modulated genes and cell cycle. Modulated genes involved in different cell cycle processes are
depicted as colored boxes along a diagram showing the five main stages (G1, S, G2, M and cytokinesis). Up-regulated genes are colored in red
whereas down-regulated genes are colored in blue. Some key regulator genes, which are not modulated by FGFR3, are colored in grey.
doi:10.1371/journal.pone.0007633.g004
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IQGAP3, LSP1 (down-regulated) and NME1 (up-regulated).
Modulated expression was identified for 24 Transcription
Factors (TFs) acting downstream of the MAPK, Wnt, Hedgehog,
TGF-b,N F kB, PI3K/AKT and calcium signaling pathways
(supplementary data S4). Several TFs belonging to families already
known to control skeletal development were differently modulated:
JUN, FOSL2, CEBPD, ID2, ID3 and ETV1/ETV5 were up-
regulated, whereas ATF5, RUNX2, SOX8 and NKX3.2 were down-
regulated.
Figure 5. Normal v. TDI chondrocytes: modulated genes, ECM biosynthesis, cytoskeleton and adhesion. Modulated genes are grouped
according to their role in these different biological processes. Up-regulated genes are colored in red whereas down-regulated genes arecolored in blue.
doi:10.1371/journal.pone.0007633.g005
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identify over-represented TF binding sites (TFBS) in 5 kb
upstream regions. About 70 TFBS were statistically over-
represented using the whole genome as a reference). In contrast,
no TFBS enrichment could be detected using the set of all
expressed genes as reference (supplementary data S4).
Furthermore, a search for differently modulated E2F targets
identified 51 genes, of which 38% were down-regulated and 62%
up-regulated. GO term enrichment analysis showed that down-
regulated genes were mainly associated with cell cycle and
division, whereas up-regulated genes were related to development,
differentiation and death (Figure 7 and supplementary data S5).
In Vitro Analysis
qPCR tests. Expression of 16 genes representative of the
biological processes highlighted by the IPA analysis was assessed
by qPCR on three control and three pathological (Y373C)
chondrocyte primary cultures (Figure 8 and supplementary data
S6). Amplification efficiencies were within a range of 0.8–1.2 and
no genomic DNA or negative control amplifications were
observed. Fold change differences between pathological and
control chondrocytes were similar to those measured by
microarray. However, lower values were observed for ID3 (2.3
instead of 3) and SEMA3 (1.8 instead of 3). The qPCR estimated
fold change for MAT2A was below the cutoff of 1.5 (1.4 instead of
2.4).
Mitosis and immunocytochemistry analysis. Mitosis in
TDI and control human primary chondrocytes was assessed by
counting cells at cytokinesis in primary cultures. Significant
differences in the frequency of cells at cytokinesis were detected
between TDI (8.3%61.2) and control cultures (13.6%60.9),
respectively, suggesting a reduced cellular proliferation in TDI
cultures (t=1.5 10
28) (supplementary data S7).
Immunocytochemistry was performed to confirm microarray
results for four transcription factors (SOX8, FOSL2, ID3,
RUNX2), two genes involved in microtubule dynamics (KIF2C
and KIF14) as well as IFT74 (intraflagellar transport), CHST3
(chondroitin sulfate biosynthesis), Noggin (BMP signaling) and
ANGPT2 (angiogenesis). Protein detection was consistent with
expression data (Figure 9 and supplementary data S8). In most
cases, in human primary or immortalized chondrocytes, differ-
ences in cytoplasmic protein staining were detected. However,
reduced nuclear levels of CHST3 and Noggin, as well as increased
perinuclear and nuclear staining of ID3 were noticed in TDI
chondrocytes. Likewise, reduced staining of KIF14 was observed
both in the cytoplasm and Golgi of mutant chondrocytes. In
addition, no obvious modification of actin fibers was observed in
the TDI chondrocytes using phalloidin and actetylated alpha-
tubulin staining.
Discussion
Status characterization of human primary chondrocyte
cultures
High levels of proliferative chondrocytic markers together with
reduced or negligible expression of hypertrophic markers con-
firmed that the primary normal and TDI chondrocytes were not
dedifferentiated and exhibited a proliferative phenotype.
FGFR3 constitutive activation modulates cell cycle
The cell cycle is a highly coordinated process, which involves
expression of a host of genes in the different cell cycle phases. Most
genes essential for S, G2, and M phases, were found to be down-
regulated in the human TDI primary chondrocyte cultures.
Conversely, genes promoting G1 progression, especially cyclin D1
were up-regulated, in agreement with previous studies [32,36].
Inhibitors of G1 progression, such as p18 were down-regulated.
These data, together with the reduced frequency of chondrocytes
undergoing cytokinesis observed in TDI cultures, are consistent
with a decrease in TDI chondrocyte proliferation and a G1 block
as observed in RCS lines upon FGF stimulation [32,36].
Interestingly, the observed increase in cyclin D1 expression is
consistent with the typical FGF mitogenic effect on most cell types
[37]. Thus, the unique cell cycle inhibition response observed in
TDI chondrocytes may occur during a later phase of the cell cycle,
e.g. the G1/S transition as cyclin A (22.8 fold change) can be rate
limiting for S-phase entry. Alternatively, it may also result from the
regulation of p107 and p130 pocket proteins, which undergo
dephosphorylation upon FGF stimulation [35,36]. PTPRG,a
member of the protein tyrosine phosphatase family previously
shown to induce pRB dephosphorylation [38], is up-regulated in
TDI chondrocytes, suggesting potential involvement in this process.
Figure 6. Normal v. TDI chondrocytes: canonical pathways affected by mutated FGFR3. Pathways are shown along the x axis of the classical
IPA bar graph. The significance cutoff is shown as an orange horizontal line. Ratios (number of modulated gene present in a given pathway divided by
the total number of genes that make up that pathway) are shown as orange points within the bar. Ratio values are shown on the right y axis.
doi:10.1371/journal.pone.0007633.g006
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PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7633Figure 7. GO terms associated with up or down-regulated E2F targets. Biological processes associated with either down-regulated or up-regulated
E2F targets were assessed using FATIGO+. Significance of GO term abundance was computed against expressed genes. Terms in the table are grouped by GO
term levels and are sorted by adjusted p-value. The normalized percentage of genes annotated to the functional term is given in the 1 vs #2 column.
doi:10.1371/journal.pone.0007633.g007
Figure 8. qPCR results. Relative expression levels are shown as a bar graph. Expression values were normalized to control in order to present
expression ratios. Fold changes are given above each bar. Significant fold changes (5% cutoff) are indicated by an asterisk (*).
doi:10.1371/journal.pone.0007633.g008
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may also be due to modulation of the ratio between activator and
repressor E2Fs. In support of this hypothesis, 38% of modulated
E2F targets were found to be down regulated in the current
dataset, and mainly associated with the cell cycle process, whereas
up-regulated E2F targets are involved in developmental and
differentiation processes. Down-regulation of E2F8 in TDI
chondrocytes (22.2 fold change) may contribute to such a
mechanism [39].
FGFR3 constitutive activation alters extracellular matrix
properties
Several basement membrane and ECM structural components
are down-regulated in TDI chondrocytes, suggesting an altered
matrix organization and turnover. A high number of modulated
genes are involved in glycosaminoglycan (GAG) and proteoglycan
biosynthesis, diversification and sulfation. Among these, hyalur-
onan synthase 3 (HAS3) was up-regulated. Over-expression of this
gene product may result in shortened high molecular weight
hydrophilic hyaluronan molecules, possibly reducing ECM
viscosity [40] and cell movement throughout the cartilage.
Likewise, changes in relative quantities of xylosyltransferases,
glucuronyltransferases, galactosyltransferases and glycosyltransfer-
ases may also alter biochemical properties and to some extent, the
function of these proteoglycans in cell adhesion, receptor
activation and long-range diffusion of signaling proteins. The
present data also provides an indication of a putative defect in
GAG sulfation, which may lead to dramatic biological effects, as
exemplified by mutations in PAPSS2, SLC26A2, gPAPP or SUMF1,
all causing skeletal dysplasias [41–44].
FGFR3 constitutive activation alters the cytoskeleton and
adhesion
Cartilage integrity and maturation depends on well-tuned
interactions with the ECM, which acts jointly with the
cytoskeleton to determine chondrocyte shape and control motility
[14]. In the TDI primary chondrocyte cultures, several differently
modulated genes are involved in adhesion and cytoskeleton
dynamics and regulate or act along the Rac1 and CDC42
RhoGTPase signaling pathways. This is in agreement with
previous studies showing dwarfism, abnormal cell shape and
disrupted columnar organization in mice lacking b1 integrin [9],
ILK [13] and Rac1 [45].
Although functions of some of these modulated genes are
somehow controversial, depending on cellular context (e.g.
ARHGDIB can both inhibit and positively regulate Rac1), these
Figure 9. Immunocytochemistry analysis. Cytoplasmic localization and reduced staining for three transcription factors (SOX8, FOSL2, RUNX2)
were observed in TDI chondrocytes (Y373C mutation). Staining for the intraflagellar transport protein (IFT74) is less marked in the mutant cells than
the controls. Cytoplasmic staining for CHST3, a protein implicated in chondroitin sulfate biosynthesis, is less marked in TDI chondrocytes. Staining for
ANGPT2 an NOGGIN in TDI chondrocytes is also less evident. Marked perinuclear staining of ID3 is observed in TDI chondrocytes. All the
immunocytochemistry staining is in line with the fold change.
doi:10.1371/journal.pone.0007633.g009
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ROCK pathways may be impaired, possibly resulting in reduced
motility. As the columnar arrangement of the proliferative zone
requires chondrocytes to undergo a gliding movement with one
cell moving on top of the other [46], these findings may provide
clues about growth plate disorganization. The protein products of
RND3, IQGAP3 and ARHGDIB, acting at the interface of
ERK1/2 and RhoGTPase pathways, may be involved in the
pathological process and would warrant further examination.
FGFR3 constitutive activation disturbs the balance
between multiple signaling pathways
The transcription factor binding site (TFBS) enrichment
analysis suggests that TDI mutations affect almost all signaling
pathways involved in chondrocyte biology. This is further
supported by the modulation of 24 transcription factors that
belong to, or act downstream of, the MAPK, Wnt, Hedgehog,
BMP/TGF-b,N F kB, PI3K/AKT and calcium signaling path-
ways.
Likewise, the expression of genes coding for several key
components of many signaling pathways is modified in TDI
primary chondrocytes, including DUSP6, MAP3K5, ZAK and
MAP2K6 in ERK1/2 and p38MAPK signaling [47–49], ID2 and
ID3 in BMP and TGFb signaling, PIK3R1, PLCG2 and PLCB4 in
inositol phosphate signaling, FOXM1 and MAPK8 [50] in JNK
signaling, DKK1 [51] in WNT signaling, (HIP) [52], RAB23 [53],
IFT74 in hedgehog signaling or NKX3.2 in PTHrP [18] and NFkB
[54] signaling. In addition, some modulated genes code for
scaffold proteins which are essential for the appropriate subcellular
location of signaling molecules. For instance, down-regulation of
CNKSR2 in TDI chondrocytes may impair the crosstalk between
MAPK and Ral pathways which is essential for proper receptor
endocytosis, cytoskeleton remodeling and DNA synthesis [55].
Likewise, down-regulation of IQGAP3 and LSP1 as well as over-
expression of NME1 may modify ERK1/2 activation upon PKC
or Ras activation [56–58].
The potentially reduced JNK signaling may lead to G1 cell
cycle arrest in TDI chondrocytes, as FOXM1 (23.1 fold change) is
known to promote proliferation and control the G1/S transitions
by acting through MAPK8 (22 fold change) [50]. Simultaneously,
increased BMP signaling and up-regulation of FOSL2, EIF4A and
RPS23 combined with ATF5 and NKX3.2 down-regulation, may
induce differentiation [18,59–62]. Altogether, these findings are
suggestive of reduced proliferation, premature cell cycle exit and
induction of differentiation.
In conclusion, signal transduction pathways represent networks
that process and integrate information from the cell environment
to regulate the spectrum of downstream targets in a context
specific manner. This study suggests that FGFR3 activating
mutations in human chondrocytes may disturb this finely tuned
process at many levels. Firstly, FGFR3 activating mutations affect
input signals (modified expression of other growth factors and
membrane bound receptors, biochemical properties of the ECM).
Secondly, FGFR3 activating mutations alter the expression of
several components of signaling pathways, possibly modifying the
responsiveness to a number of other external stimuli. Finally,
FGFR3 activating mutations alter cytoskeleton and scaffold
dynamics, resulting in improper compartmentalization and
insulation. Thus, TDI pathogeny may result from the interplay
of several signaling pathways and from a defective combination of
signaling modules. This study provides new insight into molecular
events triggered by FGFR3 mutations during endochondral
ossification. Further in vivo studies using compound transgenic
mice will now be required to study these hypotheses.
Materials and Methods
Ethics Statement
All cartilage specimens in this study were consented under an
IRB-approved protocol of informed consent through Ho ˆpital
Necker-Enfants Malades. All consents were written and signed
by the participants in accordance with the French ethical
standards.
Chondrocyte and RNA preparation
Cartilage samples were obtained from 11 medically aborted
fetuses following informed consent of parents. Chondrocytes were
isolated from the growth plate as described previously [63], plated
in flask (25 cm
2) and cultured at 37uC for 4 days in DMEM
supplemented with 10% fetal calf serum (Invitrogen). Chondro-
cytes were collected after 24 hours depletion. Total RNA was
extracted using the RNeasy isolation kit (Qiagen) and treated with
DNase I. Integrity and purity of total RNA were analyzed using a
Bioanalyser 2100 (Agilent).
Microarray hybridization and quality control
cDNA synthesis and labeling were performed on 3 mg of total
RNA using the GeneChip one-Cycle Target Labeling and Control
Reagents kit, according to the manufacturer’s protocol. Human
Genome U133plus2.0 GeneChips (Affymetrix) were hybridized,
revealed and washed according to the Affymetrix protocol.
GeneChips were scanned using a 7G scanner (Affymetrix) and
images (DAT files) were converted to CEL files using GCOS
software (Affymetrix). Quality Control of cRNA synthesis,
hybridization and data acquisition was performed according to
the manufacturer’s protocol completed with personal QC and data
visualization.
Data Analysis
Data normalization and differential analyses were performed
with the R-Bioconductor statistical environment [64]. After low
level diagnostics with the affyQCReport package, raw data were
normalized, and log2 intensity expression summary values for each
probe set was calculated using the gcRMA algorithm. Probe sets
corresponding to control genes or having a low intensity signal
(median log2 of intensity ,4) were discarded, yielding a total of
21836 probe sets for further analyses.
Preliminary analyses highlighted a strong batch effect, maybe
related to changes in culture conditions having occurred during
the sample collection phase. A two way ANOVA with robust
variance estimation was performed with the LIMMA package [65]
to evaluate effects of mutation, batch and the interaction between
them. Probe sets showing significant batch and interaction effects
(p-value,=0.001) were discarded from further analysis. Modu-
lated probe sets were then defined as having a mutation effect (p-
value,=0.05), a range2 .=1.5 and a fold change .=1.5.
Analysis of genes associated with cell functions was carried out
using Ingenuity Pathways Analysis and FATIGO+ to identify
biological processes and pathways which may be associated with
modulated gene expression. FATIGO+, as well as whole genome
rVista, were used for TFBS analysis. The Genomatix Suite was
used to identify targets of E2Fs and some modulated TFs.
Statistical significances were evaluated using the set of 21836
expressed probe sets as reference. All data are MIAME (minimum
information about a microarray experiment)-compliant and were
formatted and exported to the ArrayExpress database, according
to MIAME guidelines (ArrayExpress accession number: E-MEXP-
2276).
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cDNA were generated from 1 mg total RNA using the Verso
RT PCR kit (ABgene AB-1453). RNA samples were heated at
70uC for 5 min, placed 1 min on ice before adding a pool of
random hexamers and anchored oligo-dT 3:1 (v/v) and reaction
components, according to the manufacturer’s protocol. Reverse
transcription was performed during one hour at 50uC, followed by
two minutes at 95uC.
Quantitative PCR primers were defined using the Primer
Express software. Primers were chosen to generate 100–120 bp
PCR products spanning at least one intron, making it possible to
detect latent genomic DNA contaminations. Primer sequences are
available as supplementary data (supplementary data S6).
QPCR were performed using an ABI Prism 7300 and the
Absolute QPCR SYBER Green Mix (Abgene AB-1158). Reac-
tions were set up in 25 ml, using 50 ng of cDNA and 70 nM of
each primer, according to the manufacturer’s protocol. A three
step cycling method was used (95uC 15 s, 60–62uC1 5s ,7 2 uC
30 s) for 40 cycles and melt curves were analyzed to confirm the
specificity of the reaction.
Standard samples (3 quantity obtained by 1/100 serial dilution)
were added to measure amplification efficiencies and all
experiments were carried out in triplicate on the same cDNA
preparations. Quality control and relative quantity calculations
were performed using the qBase software [66]. Normalization was
performed with two reference genes in order to improve result
accuracy and reliability. RPLP13A, TBP, ACTB and 18S primer
sets were evaluated as potential control transcripts, based on
previous results [67] and ACTB and RPL13 were finally chosen as
endogenous control genes.
Mitosis and Immunocytochemistry analysis
Primary and immortalized chondrocytes [68] were seeded in 8
wells Lab-Tek chamber slides NUNC field with DMEM+10%
fetal calf serum (Invitrogen) in 5% CO2 at 37uC. Three different
controls and four TDI cultures (Arg248Cys or Tyr373Cys
mutations) were cultured on each slide, leaving one empty
negative control chamber. Each slide was then analyzed with a
different antibody. This design ensured that all samples were
subjected to the same conditions, thus reducing experimental bias.
For mitosis analysis, three control and three TDI primary
cultures stained by DAPI were analyzed. A total of 1200 cells in 10
random fields were counted for each category.
For immunocytochemistry, cells were fixed in 4% PFA for
20 min, permeabilized in 0.1% TritonX-100/PBS and blocked in
10% sheep or donkey serum, depending on primary antibody.
Immunocytochemistry was performed as previously described
[69], using Alexa488 or Alexa568 (Molecular Probes) secondary
antibodies. Primary antibody references and working dilutions are
provided as supplementary data S8. No background was
detectable in empty wells and when the primary antibody was
omitted. Cells were covered with mounting solution (Vector),
analyzed field by field and examined using an Olympus IX2-UCB
microscope using 20x and 40x objectives.
Immunofluorescence pictures for a given antibody were selected
as good representatives of the samples and were taken using the
same camera settings in order to allow semi-quantitative signal
comparisons.
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